| Bioactivity | Bromotetrandrine is a novel and potent inhibitor of P-glycoprotein (P-gp)-mediated multidrug resistance (MDR). Bromotetrandrine shows significant MDR reversal activity in vitro and in vivo, which may be related to the inhibition of P-gp overexpression and the increase in intracellular accumulation of anticancer agents. Bromotetrandrine is a brominated derivative of tetrandrine, which is promising for MDR modulator for tumor assessment[1][2]. |
| CAS | 62067-29-2 |
| Formula | C38H41BrN2O6 |
| Molar Mass | 701.65 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zheng L, et al. Pharmacokinetics and safety of bromotetrandrine (BrTet, W198) after single-dose intravenous administration in healthy Chinese volunteers. J Clin Pharm Ther. 2010 Feb;35(1):113-9. [2]. Jin J, et al. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Cancer Chemother Pharmacol. 2005 Feb;55(2):179-88. |
Bromotetrandrine
CAS: 62067-29-2 F: C38H41BrN2O6 W: 701.65
Bromotetrandrine is a novel and potent inhibitor of P-glycoprotein (P-gp)-mediated multidrug resistance (MDR). Bromotetr
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.